To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...
Medpage Today on MSN
Meta-Analyses Argue for Broader Use of SGLT2 Inhibitors in Chronic Kidney Disease
The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...
In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung ...
Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...
Although SGLT2 inhibitors are standard-of-care treatments for CKD, type 2 diabetes, and heart failure (HF), the drugs are underutilized in clinical practice.
The "EGFR Inhibitors Induced Skin Disorders Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...
News-Medical.Net on MSN
SGLT2 inhibitors show consistent cardio-renal protection in 70,000 patients
In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two ...
Novel Aldosterone Synthase Inhibitor Lorundrostat Shows Promise for Uncontrolled Hypertension in CKD
A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.
ACEI and ARB use in CKD has been available for over three decades, but it is still underutilized. Now, a new clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback